Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Measures of bronchodilato… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Measures of bronchodilator response of FEV1, FVC and SVC in a Swedish general population sample aged 50-64 years, the SCAPIS Pilot Study

Artikel i vetenskaplig tidskrift
Författare Kjell Torén
Björn Bake
Anna-Carin Olin
G. Engstrom
A. Blomberg
J. Vikgren
Jan A Hedner
J. Brandberg
H. L. Persson
C. M. Skold
Annika Rosengren
Göran Bergström
C. Janson
Publicerad i International Journal of Chronic Obstructive Pulmonary Disease
Volym 12
Sidor 973-980
ISSN 1178-2005
Publiceringsår 2017
Publicerad vid Institutionen för medicin, avdelningen för samhällsmedicin och folkhälsa
Institutionen för medicin, avdelningen för samhällsmedicin och folkhälsa, enheten för arbets-och miljömedicin
Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition
Institutionen för medicin, avdelningen för molekylär och klinisk medicin
Sidor 973-980
Språk en
Länkar dx.doi.org/10.2147/copd.s127336
https://gup.ub.gu.se/file/206970
Ämnesord spirometry, reversibility, COPD, epidemiology, obstructive pulmonary-disease, chronic-bronchitis, reversibility, asthma, diagnosis, copd, Respiratory System
Ämneskategorier Klinisk medicin

Sammanfattning

Background: Data are lacking from general population studies on how to define changes in lung function after bronchodilation. This study aimed to analyze different measures of bronchodilator response of forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and slow vital capacity (SVC). Materials and methods: Data were derived from the Swedish Cardiopulmonary Bioimage Study (SCAPIS) Pilot study. This analysis comprised 1,050 participants aged 50-64 years from the general population. Participants were investigated using a questionnaire, and FEV1, FVC and SVC were recorded before and 15 minutes after inhalation of 400 mu g of salbutamol. A bronchodilator response was defined as the relative change from baseline value expressed as the difference in units of percent predicted normal. Predictors of bronchodilator responses were assessed using multiple linear regression models. Airway obstruction was defined as FEV1/FVC ratio below lower limit of normal (LLN) before bronchodilation, and COPD was defined as an FEV1/FVC ratio below LLN after bronchodilation. Physician-diagnosed asthma was defined as an affirmative answer to " Have you ever had asthma diagnosed by a physician?". Asymptomatic never-smokers were defined as those not reporting physician-diagnosed asthma, physician-diagnosed COPD or emphysema, current wheeze or chronic bronchitis and being a lifelong never-smoker. Results: Among all subjects, the greatest bronchodilator responses (FEV1, FVC and SVC) were found in subjects with asthma or COPD. The upper 95th percentile of bronchodilator responses in asymptomatic never-smokers was 8.7% for FEV1, 4.2% for FVC and 5.0% for SVC. The bronchodilator responses were similar between men and women. In a multiple linear regression model comprising all asymptomatic never-smokers, the bronchodilator response of FEV1 was significantly associated with airway obstruction and height. Conclusion: When the bronchodilator response in asymptomatic never-smokers is reported as the difference in units of predicted normal, significant reversibility of FEV1, FVC and SVC to bronchodilators is 9%, 4% and 5%, respectively.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?

Denna text är utskriven från följande webbsida:
http://www.gu.se/forskning/publikation/?languageId=100000&disableRedirect=true&returnUrl=http%3A%2F%2Fwww.gu.se%2Fenglish%2Fresearch%2Fpublication%2F%3Fprint%3Dtrue%26publicationId%3D252565&publicationId=252565
Utskriftsdatum: 2019-10-22